secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001493152-24-031157
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Q2 net loss $0.47/sh; cash $7.3M; raises $3M in August offering
------------------------------------------------------------------------

- Net loss per share $0.47 for Q2 2024 vs $0.39 YoY; six-month loss $0.92 vs $0.89.
- Cash and equivalents $7.3M at June 30, 2024; raised $3.0M (net ~$2.5M) on August 8 via registered direct offering and private placement.
- Phase 1 Decoy20 trial: completed one month of weekly dosing in 3 patients at 3x10^7 dose; single dose at 7x10^7 completed.
- Presented Decoy20 data at AACR and ASCO; CSO Michael Newman chaired STING & TLR Summit.
- Cash runway expected into Q1 2025 based on current operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224031157/0001493152-24-031157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224031157/form-8k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer